Skip to main content

Latest Articles

Latest Articles

Showing 9 / 937 GLP-1 Medications articles

India's GLP-1 Opportunity: Startups Betting Big on Weight Loss
GLP-1 Medications

India's GLP-1 Opportunity: Startups Betting Big on Weight Loss

With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.

Shotlee··6 min read